Executive Summary
The EU Pharmaceutical Package is not just a regulatory update, it is a structural shift in how pharmaceutical value will be earned in Europe. Incentives and exclusivity will increasingly depend on demonstrated public health impact, timely patient access, and resilience of supply.
Although the new rules are expected to apply from 2028, the strategic implications start now: companies that wait risk losing flexibility, incentives, and competitive positioning.
Regulation is no longer only a compliance requirement. It has become a key driver of strategy, competitiveness and long‑term value creation. Companies are now expected to demonstrate not only scientific innovation, but also tangible contributions to public health priorities, access to medicines, and security of supply.
In this context, Regulatory Affairs (RA) emerges as a critical strategic partner for pharmaceutical companies. A proactive and integrated RA approach can support complex decision‑making, reduce regulatory risk and enable companies to turn regulatory change into a competitive advantage. This white paper highlights the key elements of the reform and outlines how Regulatory Affairs can actively support stakeholders in navigating and leveraging the new framework.
1. Why the EU is rewriting the rules
The previous legislative framework, largely based on Directive 2001/83/EC and Regulation (EC) No 726/2004, no longer fully addresses the challenges faced by today’s pharmaceutical sector. These include:
- uneven access to medicines across EU Member States;
- increasing shortages of essential and critical medicines;
- growing pressure on the sustainability of healthcare systems;
- the need to stimulate innovation in areas of high unmet medical need, such as antimicrobial resistance.
The EU Pharmaceutical Package introduces a policy‑driven approach that reshapes the balance between innovation, access, and sustainability.
2. What's Changing
A New Balance Between Innovation and Access
The new framework maintains a baseline of 8 years of regulatory data protection, followed by 1 year of market exclusivity. Any additional extensions are no longer automatic and are conditional upon meeting specific criteria, including:
- addressing unmet medical needs;
- generating robust and relevant clinical evidence;
- contributing to timely and broad patient access across Member States.
For orphan drugs agreement has been reached to grant 11 years of market exclusivity to ‘breakthrough orphan drugs’, i.e. when there is no medicinal product available in EU for a life threatening or severely debilitating disease and 9 years to all other orphan drugs.
This approach creates a direct link between regulatory incentives and value delivered to healthcare systems.
- Strengthened Requirements on Availability and Supply
The reform significantly reinforces obligations related to the prevention and management of medicine shortages, with a particular focus on critical and essential medicines. Marketing authorisation holders are expected to:
- implement structured shortage prevention plans;
- enhance supply chain monitoring and risk assessment;
- engage in timely and transparent communication with EU and national authorities.
- Targeted Incentives for Priority Areas
To stimulate innovation where market incentives have proven insufficient, the Package introduces targeted mechanisms, such as transferable exclusivity vouchers for priority antimicrobials, subject to safeguards to limit budgetary impact on healthcare systems.
- Regulatory Modernisation and Simplification
The reform promotes greater digitalisation of regulatory processes, streamlining of EMA procedures and stronger alignment between regulatory assessment and health technology assessment (HTA), with the aim of reducing inefficiencies and accelerating patient access.
The new EU value equation
In Europe, exclusivity will increasingly be earned through delivery, not granted by default.
Earned incentives = Clinical value + Access delivery + Supply reliability
3. What the EU Pharma Package Means for Decision-Makers
Leadership takeaways
- Exclusivity becomes conditional, not automatic, and must be earned through access and evidence strategy.
- Access is now a regulatory issue, not only a commercial one.
- Supply resilience becomes enforceable, with stronger obligations and accountability.
- Portfolio value will shift earlier, requiring risk-adjusted decisions well before 2028.
- Cross-functional governance becomes essential, as Regulatory, Clinical, Market Access and Supply are now structurally linked.
For senior leaders, the EU Pharmaceutical Package is not a distant regulatory update but a near-term strategic inflection point. Its implications go well beyond Regulatory Affairs and directly affect portfolio value, investment prioritisation, and organisational design.
Key messages for decision-makers include:
- regulatory incentives are increasingly conditional and must be earned through aligned development, access and supply strategies;
- uncertainty around effective exclusivity requires earlier and more rigorous risk-adjusted portfolio decisions;
- access, availability and resilience are now part of the regulatory value proposition, not downstream considerations;
- delayed preparation increases the risk of rushed, sub-optimal decisions once the new framework becomes fully applicable.
Companies that treat the reform as a compliance exercise risk value erosion. Those that treat it as a strategic signal can reposition early and gain competitive advantage.
4. What this means across the business
Regulatory Affairs
- shift from execution-focused activities to early strategic input on pipeline and lifecycle decisions;
- proactive interpretation of policy concepts such as unmet medical need and access obligations;
- stronger role in coordinating regulatory, HTA and supply-related requirements.
Clinical Development
- increased importance of comparator and endpoint choices aligned with both EMA and HTA expectations;
- need to generate evidence that supports not only approval, but also access and incentive eligibility;
- earlier integration of regulatory and access considerations into trial design.
Market Access
- launch sequencing and pricing strategies increasingly constrained by regulatory access expectations;
- greater need for early dialogue and alignment with regulatory strategy;
- tighter link between evidence strategy and access outcomes.
Supply and Operations
- reinforced accountability for availability and shortage prevention;
- need for structured risk assessment and resilience planning;
- closer interaction with Regulatory Affairs on compliance and authority engagement.
5. What Companies Should Start Doing Now
Although the new rules will apply after a transition period, waiting is not a neutral choice. Companies that delay preparation may face compressed timelines, limited strategic optionality and higher execution risk.
Actions that should start now include:
- embedding regulatory strategy into portfolio and pipeline governance;
- reassessing key assets against future incentive and access criteria;
- stress-testing supply chains against new availability expectations;
- strengthening cross-functional governance between Regulatory, Clinical, Market Access and Supply;
- building internal awareness at leadership level of regulatory-driven strategic risks.
Early action creates flexibility. Late action creates constraints.
6. Where Arithmos Supports Execution, Not Just Advice
Arithmos supports clients across the full journey from strategic interpretation to operational execution. Our role goes beyond advisory support and focuses on enabling tangible outcomes.
We work with clients to:
- run EU Pharma Package readiness assessments across portfolio, pipeline, and key markets
- build incentive and access-risk scoring models to guide asset prioritisation
- define cross-functional governance and operating models linking Regulatory, Clinical, Market Access and Supply
- translate reform requirements into development and evidence roadmaps aligned to EMA + HTA expectations
- design and implement shortage prevention plans, including risk monitoring, escalation paths, and authority engagement
By combining deep regulatory expertise with hands-on execution capabilities, we help clients move from understanding the reform to implementing it effectively.
Explore what the EU Pharma Package means for your portfolio, access strategy, and supply resilience, and what to start doing now.
About the Author
Head of Regulatory Affairs
Giulia began her career in R&D within the PK & Metabolism Department before moving into Regulatory Affairs, where she has built more than 25 years of expertise. Throughout her career, she has led numerous development and regulatory projects, guiding companies through complex submissions such as centralised EU registrations, CTAs, INDs, ODDs, PIPs, MAAs, and NDAs.
Her leadership has been instrumental in two major EU centralised procedures—one that contributed to a $900 million product acquisition, and another involving a life-saving antimicrobial developed in collaboration with the WHO and MMV. She also played a key role in most of the recent company/product acquisitions at her previous organisation.
Giulia brings extensive experience in global regulatory negotiations, having worked closely with authorities including the EMA, FDA, PMDA, and several non-ICH agencies.
About Arithmos
With deep expertise in the Life Science Industry, Arithmos supports companies in their digital transformation journey to achieve the best value from technology-enabled solutions and excellence in business operations.
Arithmos team share extensive knowledge of the full GxP regulated environment for both deliveries of services and technologies, and our domains range from Clinical Development, Quality & Compliance, Pharmaco-Vigilance & Safety and, Regulatory Affairs.
